Artificial saliva containing amino acid and using basic amino acid for treating dry mouth

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to chemical-pharmaceutical and cosmetic industry and represents artificial saliva containing arginine either in the free form, or in the form of a salt together with one or more of: a) a calcium ion source, b) a phosphate ion source, c) a potassium ion source, d) a magnesium ion source, e) a fluoride ion source; f) a flavour stimulating saliva flow; and/or g) a polyol humidifier.

EFFECT: invention provides creating the agent containing arginine or a salt thereof for treating, improving, slowing or preventing dry mouth.

8 cl, 3 ex

 

This application claims the priority of Patent Application United States Serial No. 61/027438, filed February 9, 2008, and claims the priority of Patent Application United States Serial No. 61/027442, filed February 9, 2008, and Patent Application United States Serial No. 61/027432; 61/027431; 61/027420 and 61/027435, filed February 9, 2008, all of the contents of these applications are incorporated in this application by reference.

The prior art INVENTIONS

Dry mouth or xerostomia is an acute or chronic condition that originally caused by lack of saliva. This may be due to underlying disease such as Sjogren syndrome, dehydration, damage to the salivary glands, alcohol or side effects of drugs. It was found that the General population of this state is increased. Tentatively, dry mouth complains from 15% to 20% of young people, and dry mouth complaining about 30-40% of people aged 60-80 years.

Xerostomia can cause patients some complications. The amount of saliva may be reduced, and it can be frothy, thick and viscous. The language can be dry, cracked, lobed, and may be infected with various bacteria and yeast fungi. The cheeks are often dry, dull and pale. Low humidity in the mouth creates difficulties what about the food, because of the lack of saliva complicated chewing and swallowing food. This also applies to a person's ability to feel the food taste and speak. In addition, the moist mucosa of the mouth is necessary in intimate relationships between people, who may also suffer as a result of dry mouth.

Patients suffering from xerostomia, also suffer from extensive carious decay of the teeth, such as tooth decay, including areas not normally susceptible to rot, such as the lower incisors and roots. One possible explanation is that a thin film is present in saliva, provides a protective barrier between the acid and the surface of the tooth, and this barrier is weakened in the absence of saliva.

There are numerous products suitable for relief of dry mouth, including moisturizing mouth rinses, gels and sprays of artificial saliva, but only a few products provide action of anti-caries effect. Current products for oral cavity for the treatment of dry mouth requires high concentrations of fluoride to reduce the risk of tooth decay.

There remains a need to develop compositions for oral hygiene and medical treatment of people suffering from dry mouth. There remains the need to develop compositions for oral hygiene and the act is mandatory to slow the development of dental caries in people, suffering from dry mouth. There remains the need to develop compositions for oral hygiene that can help with eating and speech in people suffering from dry mouth.

The INVENTION

Application of basic amino acids such as arginine, in the finished form of toothpastes known in this field, however, the inventors have revealed unexpected and surprising result when using toothpastes containing arginine bicarbonate, people suffering from xerostomia, namely, that such compositions alleviate, treat and slow the development of dry mouth. I believe that the basic amino acids, for example arginine, can be used to prevent cavities without or in the absence of fluoride, as salts of basic amino acids, for example, arginine bicarbonate, in combination with an insoluble salt of calcium, usually abrasive material for toothpaste, mimic the protective effects of saliva against caries and provide full protection of tooth enamel and roots by covering the tooth.

Thus, the invention includes a Composition of 1.0, the composition for the care of the oral cavity to treat, prevent, reduce the severity, or delaying dry mouth, containing an effective amount of basic amino acids, e.g. arginine, in free form or f is RME salt, for example, present in an amount constituting at least 1% (by weight of free base), if the finished form is a toothpaste, or 0.1%, if the finished form is a mouthwash for mouth; prepared form optionally further comprises one or more of the

i. calcium and/or source of phosphate ions, such as calcium carbonate and/or a soluble calcium salt, e.g. calcium chloride, calcium lactate;

ii. soluble phosphate salt, for example, potassium phosphate monobasic or Doonbeg potassium phosphate; and/or

iii. calcium phosphate, for example, dicalcium phosphate; a source of potassium ions, for example, potassium chloride, potassium phosphate monobasic or Doonbeg potassium phosphate and/or potassium nitrate;

iv. source of fluoride, for example, soluble salts of fluoride, such as sodium fluoride or sodium monophosphate;

v. source of magnesium, such as magnesium chloride; fragrance that causes salivation, such as capsaicin; and/or

vi. Paleologo humidifier, for example, selected from glycerol, sugar alcohols (e.g. sorbitol, xylitol and combinations thereof,

for example, any of the following songs:

1.0.1. The composition is 1.0, in which the basic amino acid is an arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutane acid,diaminopropionic acid, their salts and/or their combinations.

1.0.2. The composition is 1.0 or 1.0.1, in which the basic amino acid is L-configuration.

1.0.3. Any of the preceding compositions provided in the form of salts of di - or Tripeptide containing a basic amino acid.

1.0.4. Any of the preceding compositions, in which the basic amino acid is an arginine.

1.0.5. Any of the preceding compositions, in which the basic amino acid is an L-arginine.

1.0.6. Any of the preceding compositions, in which the basic amino acid is partially or completely in the form of a salt.

1.0.7. Composition 1.0.6, in which the basic amino acid is an arginine phosphate.

1.0.8. Composition 1.0.6, in which the basic amino acid is in the form of arginine hydrochloride.

1.0.9. Composition 1.0.6, in which the basic amino acid is an arginine sulfate.

1.0.10. Composition 1.0.6, in which the basic amino acid is an arginine bicarbonate.

1.0.11. Any of the preceding compositions, in which the salt of the basic amino acids get in the finished form in situ by neutralization of the basic amino acid or salt of the acid.

1.0.12. Any of the preceding compositions, in which the salt of the basic amino acids get by neutralization of the basic amino acids for the formation before artelino prepared mixture before connecting with a fluoride salt.

1.0.13. Any of the preceding compositions, in which the basic amino acid is present in an amount corresponding to about 0.1-20%, for example, from about 1 wt.% to about 10 wt.% of the total weight of the composition, and the weight of the basic amino acid is calculated in the form of free base.

1.0.14. Composition 1.0.11, in which the basic amino acid is present in amount of about 7.5 wt.% of the total weight of the composition.

1.0.15. Composition 1.0.11, in which the basic amino acid is present in amount of about 5 wt.% of the total weight of the composition.

1.0.16. Composition 1.0.11, in which the basic amino acid is present in amount of about 3.75 wt.% of the total weight of the composition.

1.0.17. Composition 1.0.11, in which the basic amino acid is present in amount of about 1.5 wt.% of the total weight of the composition.

1.0.18. Any of the preceding compositions in which the fluoride salt is a tin fluoride, sodium fluoride, potassium fluoride, sodium monitoroff, sodium forcelimit, ammonium forcelimit, aminopterin (for example, N'-octadecyltrimethylammonium-N,N,N'-Tris(2-ethanol)dihydrofolic), ammonium fluoride, titanium fluoride, hexapetala and combinations thereof.

1.0.19. Any of the preceding compositions, in which f is arena salt is perforat.

1.0.20. Any of the preceding compositions in which the fluoride salt is a sodium monitoroff.

1.0.21. Any of the preceding compositions where the fluoride salt is sodium fluoride.

1.0.22. Any of the preceding compositions in which the fluoride salt is present in amount of about 0.01 wt.% to about 2 wt.% of the total weight of the composition.

1.0.23. Any of the preceding compositions in which the fluoride salt provides fluoride ion in an amount of about 0.1 to about 0.2 wt.% of the total weight of the composition.

1.0.24. Any of the preceding compositions, in which a soluble fluoride salt provides fluoride ion in an amount constituting from about 50 to 10000 ppm

1.0.25. Any of the preceding compositions which is a liquid for rinsing the mouth, containing from 100 to about 250 ppm of available fluoride ions.

1.0.26. Any of the preceding compositions which is a toothpaste containing from about 750 to 2000 ppm of available fluoride ions.

1.0.27. Any of the preceding compositions in which the composition includes from 750 to 2000 ppm of fluoride ions.

1.0.28. Any of the preceding compositions in which the composition includes from 1000 to 1500 ppm of fluoride ions.

1.0.29. Any of regsetvaluea compositions in which the composition includes approximately 1450 ppm fluoride ion.

1.0.30. Any of the preceding compositions in which the pH is between about 6 and about 9, for example, of 6.5 and 7.4 or 7.5 and 9.

1.0.31. Any of the preceding compositions in which the pH is between approximately 6.5 and approximately 7,4.

1.0.32. Any of the preceding compositions in which the pH is between about 6.8 and about 7.2 for.

1.0.33. Any of the preceding compositions in which the pH is approximately neutral.

1.0.34. Any of the preceding compositions, optionally containing an abrasive substance or powder material.

1.0.35. Immediately preceding the composition in which the binder or powder material is selected from sodium bicarbonate, calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, calcium carbonate precipitated, silicon (such as silicon hydroxide), iron oxide, aluminum oxide, perlite, plastic particles, such as polyethylene, and combinations thereof.

1.0.36. Immediately preceding the composition in which the abrasive substance or powder material selected from a calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silicon (such as silicon hydroxide) and their combinations./p>

1.0.37. Any of the preceding compositions containing abrasive substance in the amount of about 15 wt.% to about 70 wt.% of the total weight of the composition.

1.0.38. Any of the preceding compositions containing the proportion of fine-grained abrasive substances constituting at least 5%, with a d50 average of <5 micrometers.

1.0.39. Any of the preceding compositions having an RDA of less than 150, for example, about 40-140.

1.0.40. Any of the preceding compositions, in which the anionic surfactant is chosen from

a. water-soluble salts of monosulfate monoglycerides of higher fatty acids (e.g. sodium salt monoculturing monoglyceride hydrogenated fatty acids of coconut oil, such as sodium N-methyl N-coquillart, sodium commericial sulfate),

b. the higher alkyl sulphates, such as sodium laurylsulfate,

c. higher alkylating sulfates, for example, the formula

CH3(CH2)mCH2(OCH2CH2)nOSO3X, where m is from 6 to 16, for example, 10, n is 1-6, for example, 2, 3 or 4, and X represents Na or K (for example, sodium Laureth-2 sulfate (CH3(CH2)10CH2(OCH2CH2)2OSO3Na)),

d. the highest alkylarylsulfonates (such as sodium dodecylbenzensulfonate (sodium lauribina ulpanat)),

e. higher alkyl sulfoacetate (such as sodium laurylsulphate (dodecyl sodium sulfoacetate), esters of higher fatty acids 1,2-dihydroxydiphenylsulfone, sulphurata (sulphacetamide potassium N-2-tillaart) and sodium laurylsarcosine),

f. and mixtures thereof.

Under "higher alkyl" refers to, for example, alkyl (C6-30. In some embodiments, implementation, anionic surfactant selected from sodium lauryl sulphate and sodium lauryl ether.

1.0.41. Any of the preceding compositions, in which the anionic surfactant is selected from sodium lauryl sulphate, sodium lauryl ether and mixtures thereof.

1.0.42. Any of the preceding compositions, in which the anionic surfactant is present in an amount constituting from about 0.3% to about 4.5% by mass.

1.0.43. Any of the preceding compositions, optionally containing surfactants selected from cationic, zwitterionic and nonionic surfactants and mixtures thereof.

1.0.44. Any of the preceding compositions containing at least one humidifier.

1.0.45. Any of the preceding compositions containing at least one humectant selected from glycerin, sorbitol, and combinations thereof.

1.0.46. Any of the preceding compositions containing xylitol.

1.0.47. Any of the preceding compositions containing at least adiposomes.

1.0.48. Any of the preceding compositions containing at least one polymer selected from polyethylene glycols, copolymers of polyphenylmethyl ester of maleic acid, polysaccharides (e.g. cellulose derivatives, such as carboxymethyl cellulose or polysaccharide resins, for example, xanthan gum or carraginanous gum) and their combinations.

1.0.49. Any of the preceding compositions containing strips or pieces of gum.

1.0.50. Any of the preceding compositions containing flavouring substance, flavouring and/or colouring agents.

1.0.51. Any of the preceding compositions containing water.

1.0.52. Any of the preceding compositions containing an antibacterial agent selected from halogenated diphenyl ether (e.g., triclosan), herbal extracts and essential oils (e.g., rosemary extract, tea extract, Magnolia extract, thymol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitiol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallium acid, extract of miswak extract, sea buckthorn), biguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), Quaternary ammonium compounds (for example, cetylpyridinium chloride (CPC), benzalkonium chloride, tetradecylammonium chloride (TPC), N-tetradecyl-4-ACELP is Didinium chloride (TDEPC)), phenolic antiseptics, hexetidine, octenidine, sanguinarine, povidone iodine, delmopinol, calyptra, metal ions (e.g., zinc salts, e.g. zinc citrate, salts of tin, copper salts, iron salts), sanguinarine, propolis and oxidizing agents (e.g. hydrogen peroxide, buffered sodium peroxyborate or peroxocarbonate), ftalievogo acid and its salts, monophthalmos acid and its salts and esters, ascorbinsaeure, oleoresin, alkylsulfate, dioctylsulfosuccinate, salicylanilide, domainbased, delmopinol, Octafinal and other derivatives of piperidine, drugs Nizina, salts of chlorite; and mixtures of any of the above.

1.0.53. Any of the preceding compositions containing anti-inflammatory compound, for example, the inhibitor of at least one of the masses of Pro-inflammatory factors selected from matrix metalloproteinases (MMP), cyclooxygenase (COX), PGE2, interleukin-1 (IL-1), IL-1β converting enzyme (ICE), transforming growth factor β1 (TGF-β1)induced synthase nitric oxide (iNOS), hyaluronidase, cathepsins, nuclear factor Kappa B (NF-κB), and kinase-related receptor IL-1 (IRAK), for example, selected from aspirin, Ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, Ketoprofen, piroxicam, meclofenamic acid, nondigital is areaway acid, and mixtures thereof.

1.0.54. Any of the preceding compositions containing antioxidant, for example, selected from the group consisting of coenzyme Q10, PQQ, Vitamin C, Vitamin E, Vitamin A, anethole-ditation, and mixtures thereof.

1.0.55. Any of the preceding compositions, in which the antimicrobial agent is poorly soluble.

1.0.56. Any of the preceding compositions containing triclosan.

1.0.57. Any of the preceding compositions containing triclosan and xylitol.

1.0.58. Any of the preceding compositions containing triclosan, xylitol and precipitated calcium carbonate.

1.0.59. Any of the preceding compositions containing an antibacterial agent in amounts as low as 0.01-5 wt.% of the total weight of the composition.

1.0.60. Any of the preceding compositions containing triclosan in the amount of 0.01 to 1 wt.% of the total weight of the composition.

1.0.61. Any of the preceding compositions containing triclosan in the amount of about 0.3% of the total weight of the composition.

1.0.62. Any of the preceding compositions containing a bleaching agent.

1.0.63. Any of the preceding compositions containing a bleaching agent selected from the bleaching-active substances selected from the group consisting of peroxides, metal chlorite, perborates, percarbonates, peroxyketal, hypochlorites and comb the Nations.

1.0.64. Any of the preceding compositions containing hydrogen peroxide or a source of hydrogen peroxide, for example, urea peroxide or a salt or complex of a peroxide (such as salts peroxyborate, peroxycarbonates, perborates, proxyselector or persulfates; for example, calcium proxyport, sodium perborate, peroxide, sodium carbonate, sodium peroxyborate and potassium persulfate).

1.0.65. Any of the preceding compositions, optionally containing an agent which inhibits or prevents the adherence of bacteria, for example, Cabral or chitosan.

1.0.66. Any of the preceding compositions, optionally containing a calcium source and a phosphate selected from (i) calcium-glass complexes, for example, calcium sodium phosphosilicate, and (ii) calcium-protein complexes, for example, casein phosphopeptide - amorphous calcium phosphate.

1.0.67. Any of the preceding compositions, optionally containing a soluble salt of calcium, for example, selected from calcium sulfate, calcium chloride, calcium nitrate, calcium acetate, calcium lactate, and combinations thereof.

1.0.68. Any of the preceding compositions, optionally containing a physiologically acceptable salt of potassium, for example, potassium nitrate or potassium chloride, in an amount effective to reduce the sensitivity of dentin.

1.0.69. Any and the preceding compositions containing from about 0.1% to about 7.5% of physiologically acceptable salts of potassium, for example, potassium nitrate and/or potassium chloride.

1.0.70. Any of the preceding compositions which is a toothpaste containing a salt of arginine, for example, arginine hydrochloride, arginine phosphate, or arginine bicarbonate; triclosan; anionic surfactant, for example sodium lauryl sulphate; and a soluble fluoride salt, for example, sodium monitoroff or sodium fluoride.

1.0.71. Any of the preceding compositions effective when applied in the oral cavity, for example, a brush, to reduce dryness in the mouth and/or to create sensations hydrating effects, and not necessarily to (i) reduce or delay the formation of dental caries, for example, tooth decay, which is due to decreased salivation, and dry mouth, (ii) reduce, repair or deceleration of early destruction of enamel, for example, which is detected by quantitative light-induced fluorescence (QLF) or electrometric diagnosis of caries (ECM), (iii) reducing or slowing demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or deceleration of gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels kislotoproduktsiya b is Cheri, (viii) to increase relative levels alginolyticus bacteria, (ix) slow formation of microbial biofilms in the oral cavity, (x) raise and/or maintain the pH of dental plaque at levels equal to at least pH 5.5 after the introduction of sugar, (xi) reduce plaque on teeth, (xiii), improve overall health, including the health of the cardiovascular system, for example, by reducing potential for systemic infection via the tissues of the mouth, and/or (xiv) reduce erosion of the teeth, (xv) whiten teeth, (xvi) immunosorbant teeth against cariogenic bacteria, (xvii) the cleansing of the teeth and oral cavity, and (xviii) reduce the destruction as a result of dry mouth during sleep.

1.0.72. Composition, obtained or realised by combining the ingredients as set forth in any of the preceding compositions.

1.0.73. Any of the preceding compositions in the form selected from means for mouthwash, toothpaste, tooth gel, tooth powder, non-abrasive gel, mousse, foam, preparations for perfuming the mouth sprays, lozenges, oral tablets, dental supplies and product care for Pets.

1.0.74. Any of the preceding compositions in which the composition is a toothpaste.

1.0.75. Any of the preceding compositions in which the composition is a dental p is STU, optional optionally containing one or more substances from the one or more substances: water, abrasive substances, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavoring agents, dyes and/or combinations thereof.

1.0.76. Any of the preceding compositions 1.0-1.0.72, in which the composition is a liquid for rinsing the mouth.

1.0.77. Any of the preceding compositions 1.0-1.0.72, in which the composition is a chewing gum.

1.0.78. Any of the preceding compositions, optionally containing breath freshener, aroma or flavouring substance.

The levels of active ingredients will vary based on the nature of the delivery system and the specific active substances. For example, the essential amino acid can be present at levels from, for example, about 0.1 to about 20 wt.% (expressed as the weight of free base), for example, from about 0.1 to about 3 wt.% for means for rinsing the mouth, from about 1 to about 10 wt.% for toothpaste for consumers or from about 7 to about 20 wt.% for a product for professional or prescribed treatment. Fluoride may be present at levels of components, n is the sample, from about 25 to about 25,000 ppm, for example, from about 25 to about 250 ppm for means for rinsing the mouth, from about 750 to about 2000 ppm for toothpaste for consumers, or from about 2000 to about 25,000 ppm for a product for professional or prescribed treatment. The levels of the antibacterial agent will vary in the same way, with the levels used in toothpaste, as, for example, from approximately 5 to approximately 15 times higher than used in mouthwash mouth. For example, the means for rinsing the mouth with triclosan may contain, for example, about 0.03 wt.% triclosan, while toothpaste with triclosan may contain about 0.3 wt.% triclosan.

The present invention also includes a method 2.0, a method of treating, slowing or weakening of dryness in the mouth, containing an introduction to the oral cavity of a patient, nojausmas in this case, for example, those suffering from dry mouth, compositions for the care of the oral cavity, containing the basic amino acid in free form or salt form, for example, any one of compositions 1.0-1.0.78.

Additional embodiments of the present invention also include the following methods:

2.1 2.0 Way in which the method is also effective in (i) is the reduction or slowing down the formation of dental caries, (ii) reduce, repair or slowdown of the early destruction of enamel, for example, which is detected by quantitative light-induced fluorescence (QLF) or electrometric diagnosis of caries (ECM), (iii) the reduction or slowing demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) the reduction or slowing of gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels kislotoproduktsiya bacteria, (viii) increase the relative levels alginolyticus bacteria, (ix) slowing the formation of microbial biofilms in the oral cavity, (x) raise and/or maintain the pH of dental plaque on the levels of at least pH 5.5 after the introduction of sugar, (xi) reduce plaque on teeth, (xiii) improving overall health, including the health of the cardiovascular system, for example, by reducing potential for systemic infection via the tissues of the mouth, and/or (xiv) reduce erosion of the teeth, and/or (xv) the cleansing of the teeth and mouth.

2.2 Methods 2.0 or 2.2, in which the composition includes at least 7.5% arginine.

2.3 Methods 2.0-2.2, in which the composition includes at least 10% of arginine bicarbonate.

2.4 Methods 2.0-2.3, in which the composition includes at least 5% of the humidifier.

2.5 Methods 2.0-2.4, in which PAC is UNT prone to dryness in the mouth.

2.6 methods of 2.0 to 2.5, in which the patient suffers from dry mouth.

2.7 Methods 2.0-2.6, in which the patient experiences difficulty when chewing food as a result of dry mouth.

2.8 Methods 2.0-2.7, in which the patient has difficulty swallowing as a result of dry mouth.

2.9 Methods 2.0-2.8, in which the patient has difficulty with speech as a result of dry mouth.

2.10 Methods 2.0-2.9, in which the patient also suffers from opportunistic infections language as a result of dry mouth.

2.11 Methods 2.0-2.10, in which the dry mouth is caused by disease.

2.12 Methods 2.0-2.11, in which the patient is treated by medication, and the specified medication causes the specified dry mouth.

2.13 Methods 2.0-2.12, where dry mouth is a chronic.

2.14 Methods 2.0-2.13, in which the composition comprises from about 7.5% to about 25.0% of arginine.

2.15 Methods 2.0-2.14, in which the composition is a toothpaste.

2.16 Methods 2.0-2.15, in which the composition is a toothpaste.

2.17 Methods 2.0-2.16, in which the composition is a gel.

2.18 Methods 2.0-2.17, in which the composition is applied in the mouth with a toothbrush.

2.19 Methods 2.0-2.15, in which the composition is particularly the liquid for rinsing the mouth.

2.20 Methods 2.0-2.19, in which the patient uses way more often than once a day.

2.21 Methods 2.0-2.20, in which the patient applies the method on a daily basis.

The present invention also considers the application of the basic amino acid in free form or salt form, for example, arginine, for example, as provided in any one of compositions 1.0-1.0.78, for the treatment, amelioration, slow and/or prevent dry mouth.

The present invention additionally provides the use of a basic amino acid, in free form or salt form, for the manufacture of drugs for treatment, improve the condition, slowing or preventing dry mouth.

The present invention additionally provides a basic amino acid, in free form or salt form, for use in treating, improving, slowing or prevention of dry mouth.

DETAILED description of the INVENTION

The present invention provides methods and compositions for treatment, prevention, regulation or deceleration of xerostomia in suffering by the patient. In one embodiment, a patient suffering from xerostomia or is predisposed to xerostomia due to illness or injury. In another embodiment, a patient suffering from xerostomia or is predisposed to xerostomia in R is the result of the treatment (therapy) drugs, that cause xerostomia and dry mouth is a side effect of the medication.

The term "treatment" or "improvement" is used in this application to indicate that the use of a composition of the present invention improves the condition of the patient, preferably a mammal, more preferably human.

The term "slow" is used in this application to indicate that the use of a composition of the present invention deferreth the onset of the condition, for example, 6 hours, 12 hours, 24 hours, 48 hours or 96 hours following the introduction of the composition.

The term "prevent" does not mean that a particular state will be completely eliminated in the future, rather that a specific pathological condition will be excluded until such time as the patient is able to enter the composition of the present invention for the second time, for example, within 12 hours, 24 hours, 48 hours or 96 hours from the initial injection.

Without intending to be bound by a particular theory, it is assumed that a significant factor in the beneficial effect of arginine is that arginine can be metabolized by certain types of bacteria, for example,S. sanguisthat is not cariogenic and which competes with karigasniemi bacteria, such asS. mutansfor the location on the teeth and in the mouth. Orginality the ski bacteria can use arginine and other basic amino acids for the production of ammonia, increasing thereby the pH of their surrounding microenvironment, whereas criogenia bacteria metabolize sugars to produce lactic acid, which helps lower the pH of plaque and demineralization of the teeth, leading ultimately to the formation of cavities. I believe that the systematic use of a composition of the invention will eventually lead to a relative increase alginolyticus bacteria and the relative reduction cariogenic bacteria, leading to an increased pH of the dental plaque (despite the fact that the composition of the invention typically has a neutral pH, since the amino acid is neutralized with inorganic oxanilate). I believe that the effect of increasing pH can be achieved in compositions that essentially does not contain fluoride. Also consider the effect of increasing pH can mechanically be separate from and supplementary to the action of fluoride, consisting in promoting remineralization and strengthen tooth enamel.

The concentration of arginine in the compositions for oral care mouth for the action of anti-caries action can be approximately 1.5%. Higher concentrations of arginine can be used to help sensitive teeth, for example, from approximately 3,75% to approximately 7,50% arginine, in the form of ready-made forms, completely closing from Richie dentinal tubules (development paths of pain), and providing effective pain. 't bother yourself by theory, it is expected that even higher levels of arginine, for example, more than 7,50%, i.e. from approximately 7.50% to about 25%, from about 8.0% to about 20%, from about 9% to about 15%, or approximately 10% cover the teeth, gums and/or oral cavity, leaving a feeling that the oral cavity moist or gidratirovana.

Compositions of the present invention can be in the form of a toothpaste containing additional ingredients selected from one or more substances: water, abrasive substances, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavoring agents, dyes and/or combinations thereof.

Basic amino acids that can be used in the compositions and methods of the invention include not only natural basic amino acids such as arginine, lysine and histidine, but also any basic amino acid having a carboxyl group and the amino group in the molecule, which are water soluble and provide an aqueous solution with a pH of 7 or more. Accordingly, the basic amino acids include, but are not limited to, arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutane acid, dia is isopropionate acid, their salts or combinations thereof. In a separate embodiment, the basic amino acid selected from arginine, citrulline and ornithine. In certain embodiments of the implementation, the basic amino acid is an arginine, such as L-arginine, or its salt.

Compositions of the invention are intended for topical application in the oral cavity, and therefore salt for use in the present invention should be safe for such use, provided the quantities and concentrations. Suitable salts include salts known in this area as pharmaceutically acceptable salts, which are usually considered as physiologically acceptable provided in quantities and concentrations. Physiologically acceptable salts include salts derived from pharmaceutically acceptable inorganic or organic acids or bases, for example, salts of accession acid obtained with acids which form a physiological acceptable anion, for example, salt is hydrochloride or bromide, and salt attaching the base obtained through the grounds, which form a physiologically acceptable cation, for example, salts derived from alkali metals such as sodium and potassium, or alkaline earth metals such as calcium and magnesium. Physiologically acceptable salts can be obtained, since IP is the use of standard procedures, known in this field, for example, by reacting a sufficient amount of basic compound such as an amine with a suitable acid in a state of physiologically acceptable anion.

In a different implementation, the basic amino acid is present in amount of about 7.5 wt.% to about 25 wt.% by weight of the total composition, from about 1 wt.% to about 10 wt.% of the total weight of the composition, for example, about 1.5 wt.%, 3.75 wt.%, 5 wt.% or 7.5 wt.% of the total weight of the composition.

Compositions for oral care mouth can additionally include one or more sources of fluoride ions, for example, a soluble fluoride salt. A wide variety of substances, giving the fluoride ions may be used as sources of soluble fluoride in the present compositions, and such substances are known qualified specialists in this field. Examples of suitable substances, giving the fluoride ions can be found in U.S. Patent No. 3535421, Briner et al.; U.S. patent No. 4885155, Parran, Jr. et al., and U.S. Patent No. 3678154, Widder et al., included in this application by reference.

Typical sources of fluoride ions include, but are not limited to, tin fluoride, sodium fluoride, potassium fluoride, sodium monitoroff, sodium forcelimit, ammonium F. orselect, aminopterin, ammonium fluoride, and combinations thereof. In certain embodiments of the implementation of a source of fluoride ion comprises tin fluoride, sodium fluoride, sodium monitoroff, and mixtures thereof.

In certain embodiments of the implementation, composition for oral care mouth of the invention may also contain a source of fluoride ions or torpedograss ingredient in amounts sufficient to provide from about 25 ppm to 25,000 ppm of fluoride ions, typically at least about 500 ppm, for example, from about 500 to about 2000 ppm, for example, from about 1000 to about 1600 ppm, for example, approximately 1450 ppm Suitable level of fluoride will depend on the specific application. Liquid for rinsing the mouth, for example, would typically contain from about 100 to about 250 ppm of fluoride. Toothpaste for obsepechivajushchego application would typically contain from about 1000 to about 1500 ppm, with children's toothpaste contains a little less. Toothpaste or coating for professional application could contain up to 5000 or even 25000 ppm of fluoride.

In certain embodiments of the implementation, composition for oral care mouth of the invention may contain a source of fluoride ions or torpedograss ingredient in the number who twah, sufficient to provide from about 100 ppm to 10000 ppm of fluoride ions, for example, 1000-2000 ppm

Compositions of the invention may contain calcium phosphate abrasive substance, such as tricalcium phosphate (Ca3(PO4)2), hydroxyapatite (Ca10(PO4)6(OH)2) or dicalcium phosphate dihydrate (CaHPO4•2H2O, also sometimes referred to in this application as DiCal), or calcium pyrophosphate.

The composition can include one or more abrasive substances known to specialists in this field, for example, silicon abrasives such as precipitated silica, having an average particle size equal to about 20 microns, such as Zeodent 115®, marketed by J. M. Huber. Other suitable abrasives include sodium metaphosphate, potassium metaphosphate, aluminum silicate, calcined alumina, bentonite or other containing silicon substances or their combinations.

Silicon abrasive polishing materials suitable for this application, as well as other abrasive substances, as a rule, have an average particle size ranging between about 0.1 and about 30 microns, between about 5 and about 15 microns. Silicon abrasive substance can be precipitated silica or silica gels, such as craniofacially, described in U.S. Patent No. 3538230, Pader et al., and U.S. Patent No. 3862307, Digiulio, both included in this application by reference. Specific silica xerogels are pushed onto the market W. R. Grace & Co., Davison Chemical Division under the trade name Syloid®. Substances deposited silicon include substances, marketed by J. M. Huber Corp. under the trade name Zeodent®including silicon , having the designation Zeodent 115 and 119. Data silicon abrasive substances described in U.S. Patent No. 4340583, Wason included in this application by reference.

In certain embodiments of the implementation, abrasive materials suitable for practical use compositions for the care of the oral cavity, in accordance with the invention include silica gels and precipitated amorphous silicon having a coefficient of absorption of approximately less than 100 cm3/100 g of silicon and in the range of approximately 45 cm3/100 g to about 70 cm3/100 g silica. The absorption coefficients measured using ASTA Rub-Out Method D281. In certain embodiments of the implementation, silicon substances are colloidal particles having an average particle size of about 3 microns to about 12 microns, and from about 5 to about 10 microns.

In a separate vari is ntah implementation powder material or abrasive materials include a large portion of very fine particles, for example, having a d50 less than about 5 microns, for example, fine-grained silicon (SPS)having a d50 of about 3 to about 4 microns, for example, Sorbosil AC43®(Ineos). Such small particles in particular are used in the finished form, intended to reduce hypersensitivity. Fine-grained component may be present in combination with a second abrasive substance with larger particles. In certain embodiments of the implementation, for example, ready form includes from about 3 to about 8% of SPS and from about 25 to about 45% conventional abrasives.

Silicon abrasive substances with a low coefficient of absorption, especially suitable for practical use of the invention, moving the market Davison Chemical Division, W.R. Grace & Co., Baltimore, Md. 21203 under the trade designation Sylodent XWA®. Sylodent XWA 650®silicon hydrogel composed of particles of colloidal silica having a water content of about 29% by weight, on average, from about 7 to about 10 microns in diameter, and with a coefficient of absorption, comprising less than about 70 cm3/100 g of silicon, are an example of the silicon and rasinovo substances with low oil absorption, suitable for the practical application of the present invention. Abrasive substance is present in a composition for caring for the oral cavity of the present invention at a concentration factor of approximately 10 to approximately 60% by weight, in another embodiment from about 20 to about 45% by weight, and in another embodiment from about 30 to about 50% by weight.

Compositions for oral care mouth of the invention may also include an agent that increases the amount of foam, which is formed by the cleaning brush to the oral cavity. Such agents are known qualified specialists in this field. Illustrative examples of agents that increase the amount of foam include, but are not limited to polyoxyethylene and certain polymers, including, but not limited to, alginate polymers.

Polyoxyethylene may increase the amount of foam and the density of the foam formed by the component carrier of care for the oral cavity of the present invention. The polyoxyethylene is also known as polyethylene glycol ("PEG") or polyethylene oxide. Polyoxyethylene suitable for this invention will have a molecular weight comprising from about 200,000 to about 7000000. In one embodiment, the molecular weight will be part of the best from about 600,000 to about 2000000, in another embodiment, from approximately 800,000 to about 1000000. Polyox® is a trade name for a polyoxyethylene with a high molecular weight, manufactured Union Carbide.

Polyoxyethylene may be present in an amount constituting from about 1% to about 90%, in one embodiment, from about 5% to about 50%, and in another embodiment from about 10% to about 20% by weight of the component carrier of care for the oral cavity of the present invention a composition for caring for the oral cavity of the present invention. Dosage foaming agent in the composition for the care of the oral cavity (i.e., single dose) ranges from about 0.01 to about 0.9 percent by weight, from about 0.05 to about 0.5% by weight, and in another embodiment from about 0.1 to about 0.2% by weight.

Another agent, optionally included in the composition for oral care mouth of the invention is a surfactant or a mixture of compatible surfactants. Suitable surfactants are the surfactants is quite stable within a wide pH range, for example, anionic, cationic, nonionic or zwitterionic surfactants. Suitable surfactants are described more fully, for example, in U.S. Patent No. 3959458, Agricola et al.; U.S. patent No. 3937807, Haefele; and U.S. Patent No. 4051234, Gieske et al., included in this application by reference. The preferred surfactant is sodium lauryl sulphate.

The surfactant or mixture of compatible surfactants can be present in the compositions of the present invention at a concentration factor of about 0.1% to about 5.0 percent, in another embodiment from about 0.3% to about 3.0 percent, and in another embodiment from about 0.5% to about 2.0% of the weight of the entire composition.

Compositions for oral care mouth of the invention may also include flavoring agent. Flavoring agents used in the practical application of the present invention, well-known qualified specialists in this field and may include essential oils, and various corrective taste aldehydes, esters, alcohols, and similar substances. Flavoring agent included in the composition for the oral cavity at a concentration factor of approximately 0.1 to approximately 5% by weight and from about 0.5 to about 1.5% by weight. Dosage flavoring agent in a single dosage composition for the care of the oral cavity (i.e., single dose) ranges from about 0.001 to 0.05% by weight, and in another embodiment from about 0,005 0,015% by mass.

Compositions for care C the oral cavity and methods of the invention can also optionally include one or more chelat forming agents, capable of forming a complex with the calcium found in the cell walls of bacteria. The binding of calcium weakens the bacterial cell wall and enhances the lysis of bacteria. Hepatoblastoma agents are well known qualified specialists in this field, for example, soluble pyrophosphates either in hydrated or non hydrated forms. An effective amount of pyrophosphate salt used in the present compositions is generally sufficient to provide at least 1.0 wt.% pyrophosphate ions, from about 1.5 wt.% to about 6 wt.%, from about 3.5 wt.% to about 6 wt.% such ions.

Compositions for oral care mouth or methods of the invention also optionally include one or more polymers, known qualified specialists in this field. Such polymers may include polyethylene glycols, copolymers polivinilovogo ester of maleic acid, polysaccharides (e.g. cellulose derivatives, e.g. carboxymethylcellulose, or polysaccharide gums, for example xanthan gum or karragenana gum). Polymers suitable for use may include Gantrez AN 139 (M.W. of 500,000), AN 119 (M.W. 250,000 in) and S-97 Pharmaceutical Category (M.W. 70000), GAF Chemicals Corporation. Suitable polymers may also include gamopolis the ry substituted acrylamides and/or homopolymers of unsaturated sulfonic acids and their salts, in particular, when the polymers based on unsaturated sulfonic acid selected from acrylamidoglycolate sulfonic acids such as 2-acrylamide-2-methylpropanesulfonic acid having a molecular weight comprising from about 1000 to about 2000000 described in U.S. Patent No. 4842847, Jun. 27, 1989 Zahid included in this application by reference. Another suitable class of polymeric agents include polyaminoamide, in particular, polyaminoamide containing proportions of anionic surface-active amino acids such as aspartic acid, glutamic acid and phosphoserine, as disclosed in U.S. Patent No. 4866161 Sikes et al., included in this application by reference.

Compositions and methods of the present invention may also include a thickening agent to provide the desired consistency, or stabilize or improve characteristics of the finished form. Such thickeners known qualified specialists in this field, for example, carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose and water soluble salts of cellulose ethers such as sodium carboxymethylcellulose and sodium karboksimetiltselljuloza. It may also include natural gums, such as karaya, Arabian gum, and tragacanth gum. Colloidal magnesium-aluminum enclosure the Oia silicate or finely dispersed silicon can be used as a component zagustiteleyj compositions to further improve the texture of the composition. In certain embodiments of the implementation, the thickeners are present in an amount constituting from about 0.5% to about 5.0 percent by weight of all the applied composition.

Compositions and methods of the present invention can also optionally include one or more enzymes. Suitable enzymes include enzymes, known qualified specialists in this field, and may include protease, glucanohydrolase, endoglycosidase, amylase, Athanasy, lipase and mucinase or compatible mixtures thereof. Enzymes suitable for use in the present invention are disclosed in U.S. Patent No. 5000939 Dring et al., U.S. patent No. 4992420; U.S. Patent No. 4355022; U.S. Patent No. 4154815; U.S. Patent No. 4058595; U.S. Patent No. 3991177; and U.S. Patent No. 3696191, all of them are included in this application by reference. The enzyme mixture of some combination of enzymes in the present invention ranges from about 0.002% to about 2.0% in one embodiment, or from about 0.05% to about 1.5% in another embodiment, or in another embodiment from about 0.1% to about 0.5%.

Water may also be present in the composition for oral cavity of the invention. The water used in obtaining commercial compositions for the oral cavity, is preferably deionized and the s-containing organic pollutants. Water, usually compensates for the balance of the compositions and includes free water which is added plus the amount which is introduced with other substances, such as sorbitol or any of the components of the invention.

The present invention may contain a humectant to prevent solidification of the composition when exposed to air, and to assist in hydrating the oral cavity. Certain humectants can also impart desirable sweet taste or flavor of the toothpaste composition. The humectant, on a pure humidifier basis, as a rule, includes from about 15% to about 70% in one embodiment, or from about 30% to about 65% in another embodiment, by weight of the toothpaste composition.

Suitable humectants include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, propylene glycol, and other polyols, and a mixture of these humidifiers. A mixture of glycerin and sorbitol can be used in certain embodiments of the implement as a moisturizing component of the composition of toothpaste in the application.

In addition to the above components, embodiments of the present invention can contain a variety of optional ingredients of toothpaste, some of which are described below. Long the performance communications ingredients for example, include, but are not limited to, adhesive agents, foaming agents, flavoring agents, sweeteners, additional agents against dental plaque, abrasive agents, and coloring agents. These and other optional components are additionally described in U.S. Patent No. 5004597 Majeti; U.S. Patent No. 3959458 Agricola et al. and U.S. Patent No. 3937807 Haefele, all of them are included in this application by reference.

Compositions and methods according to the invention are suitable for treatment of dry mouth, and do not necessarily protect teeth by promoting recovery and remineralization, in particular, to reduce or delay the formation of dental caries, reduce, or slow demineralization and promote remineralization of the teeth, reduce hypersensitivity of the teeth and reduce, repair or deceleration precariously destruction of the enamel, e.g., as detected by quantitative light-induced fluorescence (QLF) or electrometric diagnosis of caries (ECM). Quantitative light-induced fluorescence is a system of visible light, which enables early detection precariously damage to the enamel. Healthy teeth fluoresce in the visible light; deionized teeth are not fluoresce or fluoresce tol is to a lesser extent. The area of demineralization can be quantified, and its progression is monitored. The conductivity measurement uses the fact that the fluid-filled tubules exposed when demineralization and erosion of enamel, conduct electricity. Therefore, increasing the conductivity of the patient's teeth may indicate a demineralization. Thus, compositions of the invention suitable for a method of reducing precariously destruction of enamel (as measured by QLF or ECM) refer to compositions that do not contain effective amounts of fluorine and/or arginine.

Essentially, the composition of the invention is suitable not only for the treatment of dry mouth, but also for treatment of other conditions of the oral cavity and for cleansing the mouth, and provide improved ways to promote oral health.

Improving oral health also provides benefits for overall health, because the tissues of the mouth can be a gateway for systemic infections. Good oral health is connected to overall health, including the health of the cardiovascular system. Compositions and methods of the invention provide a special benefit due to the basic amino acids, especially arginine, which are sources of nitrogen, which provides the Ooty synthesis of NO and, therefore, improves microcirculation in the tissues of the oral cavity. Providing a lower pH environment of the oral cavity is also useful to reduce gastric upset and creates an environment less suitable for Heliobacter, which is associated with ulcers of the stomach. Arginine in particular is required for high expression of specific receptors of immune cells, such as receptors of T-cells, so that arginine can improve effective immune response. Compositions and methods of the invention, therefore, is suitable for improving overall health, including the health of the cardiovascular system.

Compositions and methods according to the invention can be included in the composition for the oral cavity for the care of mouth and teeth, such as tooth paste, transparent toothpastes, gels, rinses for oral sprays and chewing gum.

As used throughout the application, the ranges are used as conditional values to describe any value that is within range. Any value within the range can be selected as the limit of the range. In addition, all references cited in this application is thereby incorporated by reference in its entirety. In the event of a conflict in the definition of the present disclosure and the definition of the given SS the CTL, dominates the present disclosure. It is clear that, when the finished form described, they can be described in terms of their ingredients, which are common in this area, despite the fact that these ingredients can react with each other in real ready form when it is received, stored and used, and it is assumed that such products should be covered are described in finished form.

The following additional examples describe and demonstrate illustrative embodiments of within the scope of the claims of the present invention. The examples are given solely for illustration and should not be construed as limiting the present invention, since there are numerous ways without going beyond the nature and scope of its legal claims. Various modifications of the invention in addition to the modifications shown and described in this application should be comprehensible to qualified specialists in this field and implied covered by the attached claims.

Example 1 - composition of the toothpaste

The composition of the toothpaste is obtained from the following ingredients to obtain toothpaste that has 7.50 wt.% arginine.

Deionized water 7,400
Glycerin21,000
Carboxymethyl cellulose0,500
Saccharin0,250
Salt of the basic amino acids (arginine bicarbonate)10,000
Calcium carbonate29,000
Silicon dioxide31,000
Flavor0,750
Colored solution (1% FD&C Blue#1)0,100

Example 2 - Studies on patients

Eight patients suffering from dry mouth, provided the composition of EXAMPLE 1. Patients were instructed to brush their teeth with the composition of EXAMPLE 1 twice a day and record your observations regarding the condition of dry mouth, before applying, on day 4 and day 8.

Before applying toothpaste, 7 patients suffer from dry mouth during the whole day; four patients also suffer from dry lips and tongue; two patients have difficulty swallowing; 3 patients have difficulty in eating, speaking and sleeping due to dry mouth.

On day 4 the majority of PAC the clients feel the moisture of the mouth from the composition, sensation in the oral cavity remained. No patient thinks that the composition makes the mouth dry. 25% of patients indicate that he felt the mouth is smooth, moist and hydrated.

On day 8 the majority of patients believe that the composition provides attenuation of dryness in the mouth, leaving the mouth feeling wet, pleasure and smoothness.

Example 3: the composition of the artificial saliva containing arginine

The composition of the artificial saliva is produced from the following ingredients:

SOURCE MATERIALWEIGHT %
Deionized water96,26815
Xylitol2,00000
L-Arginine0,50000
Hydroxyethyl cellulose0,43000
Flavor0,40000
Methylparaben0,20000
Doonally potassium phosphate0,08000
Potassium chloride0,06200
0,04300
The dihydrate of calcium chloride0,01000
Magnesium chloride0,00590
Food coloring0,00050
Sodium fluoride0,00045
ONLY100,00000

1. Artificial saliva containing arginine in free or salt form, together with one or more of the
A. source of calcium ions,
b. the source of phosphate ions,
C. source of potassium ions,
d. source of magnesium ions,
that is, the source of fluoride ions;
f. flavoring, which stimulates salivation; and/or
g. Jalilova humidifier.

2. The application of the basic amino acid in free form or salt form for the manufacture of artificial saliva defined by claim 1, for treatment, improvements, slowing or preventing dry mouth.

3. The use according to claim 2, in which the basic amino acid is an arginine.

4. The use according to claim 3, in which arginine is in the form of arginine bicarbonate.

5. The use according to any one of claim 2 to 4, where artificial saliva additionally includes one or more of the
A. the source of calcium ions is,
b. the source of phosphate ions,
C. source of potassium ions,
d. source of magnesium ions,
that is, the source of fluoride ions;
f. flavoring, which stimulates salivation;
g. Paleologo humidifier,
h. and their combinations.

6. The use according to claim 5, where artificial saliva is a toothpaste.

7. The use according to claim 5, where artificial saliva is a rinse for the mouth.

8. The use according to claim 7, where the rinse for the mouth is an artificial saliva containing ions selected from calcium, phosphate, potassium, magnesium, and combinations thereof.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an agent for local treatment of periodontal diseases, on the basis of organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O, containing therapeutic supplements, differing by the fact that the therapeutic supplements are presented by ketoprofen and methyluracil in the following proportions, wt %: ketoprofen - 0.5 - 1.0; methyluracil - 1.0 - 1.5; organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O - up to 100.

EFFECT: invention provides creating the effective agent applicable in the integrated therapy for treating the inflammatory periodontal diseases.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry. Method includes processing perforated root canal and perforation zone with laser irradiation and covering perforation with sealing material. Introduction of light-guide into perforated root canal is carried out. In processing by laser irradiation translational increase of its power parameters is used. During the first session processing is carried out with power 0.5 W, during the second session - 0.75 W, during the third - 1.5 W. Additionally ozone therapy with saturated physiological solution is performed. Time of saturation with ozone is 5 minutes. Concentration of ozone dissolved in physiological solution is 8.8-9.6 mg/l.

EFFECT: method is painless, does not require carrying out local anesthesia, excludes allergic reactions, ensures optimal bactericidal and bacteriostatic effect, which makes it possible to efficiently stop inflammation and reconstruction of bone tissue, reduces number of complications.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to dentistry, and concerns preparations for preventing and treating the diseases of periodontal membrane and oral mucosa. That is ensured by using a pharmaceutical composition in the form of a gel which contains metronidazole benzoate, chlorhexidine gluconate as an active substance and additionally the ingredients specified in a group of alpha-, beta-, gamma-, recombinant interferon.

EFFECT: invention provides reducing the length of treatment in the patients with inflammatory periodontal diseases due to the wide spectrum of action of the composition, prolonged fixation on gums, which accelerates the regeneration of the oral mucosa.

2 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dentistry, and may be used for local therapy of inflammatory periodontal diseases. That is ensured by the daily applications of powdered cellulose surgical cotton on a dentogingival edge after curettage to normalise the microcirculation and hemodynamic values.

EFFECT: method provides higher clinical effectiveness in periodontal diseases, reduced complications and disability periods due to normalising the free radical levels in the damaged tissue while reducing inflammation and accelerating the process of epithelialisation of periodontal tissues.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and methods of such compositions application. Claimed composition for oral cavity care contains amorphous quartz and source of ions of bivalent tin, with average size of amorphous quartz particles constituting from 1 to 20 microns. Version of composition additionally includes one or more essential oils and chelant. Method of oral cavity care includes stage, at which upper said composition is introduced into subject's oral cavity.

EFFECT: application of amorphous quartz (fuse quartz) as abrasive in mixture of composition for oral cavity care ensures good compatibility with ions of bivalent tin with effective and safe cleaning of dental tissues.

17 cl, 2 ex, 30 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to composition for oral cavity care and methods of its application. Claimed is composition for oral cavity care, which contains: arginine, in free form or in form of salt in amount from 0.1 to 20 wt % of total composition weight; triclosan in amount from 0.01 to 5 wt % of total composition weight; anionic polymer, which is a copolymer of methyl vinyl ether and maleic anhydrate; anionic surfactant in amount from 0.01 to 10 wt % of total composition weight; soluble fluoride salt in amount from 0.01 to 2 wt % of total body weight, in order to provide 50-25000 ppm of weight of fluoride ions, in which soluble fluoride salt or source of fluoride ions is selected from sodium fluoride, sodium monofluorophosphate and their mixtures; and abrasive material, which contains fraction of minor particles, constituting at least about 5 wt % of total composition weight, and in said fraction minor particles have average diameter d50 smaller than 5 mcm.

EFFECT: application of composition for oral cavity care along with improved delivery of antibacterial agent provides additional advantages in acceleration of remineralisation and restoration of precarious affection foci due to combination of fluoride and arginine, as well as due to application of finely disperse abrasive as composition component.

11 cl, 1 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and to methods of their application. Claimed are compositions for oral cavity care, which contain effective amounts of arginine in free or salt form, anionic surface active substance, halogenated diphenyl ether, anionic polymer, and precipitated calcium carbonate, which has d50 from approximately 0.5 to approximately 3 micrometres.

EFFECT: compositions are efficient, in particular, for reduction of bacteria adherence to tooth surface in subject's oral cavity, in addition, chemical composition provides favourable effect in activation of remineralisation, elimination of pre-caries damage and strengthening healthy state of oral cavity along with intensification of taste properties of formulation of preparation for oral cavity care and increase of general acceptability pf product for consumers.

33 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapeutic dentistry, and is intended for treatment of pulpitis, apical and marginal dental periodontitis. Drug processing of root canal is carried out. Canal is dried. After that, root canal of tooth is filled with liquid No 1 - solution of subacid magnesium fluoric silicate from composition of "Dentin-hermetising liquid". Active needle electrode of device for carrying out electro- or depot phoresis is introduced into canal and transcanal electrophoretic introduction of ions, contained in liquid, into dentin tubes of tooth root is performed. Amount of electricity, passing through tissues of tooth root tissues, constitutes from 1 to 5 mA X min, with current value from 0.1 to 1 mA. After that root canal is dried with air and electrophoresis of liquid No 2 - alkaline suspension of highly-dispersive calcium hydroxide from composition "Dentin-hermetising liquid" is carried out at the same parameters as the first liquid. Root canal is dried with air and filled by traditional method.

EFFECT: method makes it possible to reduce number of complications and increase efficiency of treatment of pulpitis, apical and marginal periodontitis due to deep transcanal electrophoretic fluoridation of tooth root dentin.

7 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapeutic dentistry, and can be used in treatment of deep dental caries. For this purpose preparation of caries cavity with its further antiseptic processing with ozone-oxygen mixture possessing high bactericidal effect is carried out. Ozone concentration in mixture constitutes 30-40 mcg/ml. Processing is carried out for 25-40 seconds. After that, self-hardening radiopaque material, containing calcium hydroxide "Life" is used as medicinal padding and filling is performed.

EFFECT: method makes it possible to perform tooth filling during the first visit due to antiseptic processing not only on the surface of caries cavity, but in dentin tubes.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely therapeutical stomatology and may be used for treating the patients suffering generalised periodontitis. That is ensured by periodontal care and antiseptic preparation, topical treatment with "Lesnoy Balsam" involving applications to a region of inflammation in an amount of 0.05-0.2 g and introduction into gingival pockets. Length of the procedures is 15 minutes twice a day; the therapeutic course is 5-6 days: the general treatment includes the preparation "Ginkoum" 1 capsule three times a day; the therapeutic course is 5 weeks.

EFFECT: invention enables a high therapeutic effect by blocking pathogen flora, improved regional gingival haemodynamics, wound healing and epithelising actions, reduced perivascular oedema and vascular metabolic improvements with no discomfort to the patient.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at treating and preventing hepatic encephalopathies. There are presented composite formulations containing various combinations of L-carnitine, acetyl-L-carnitine, succinate, L-glutamate, L-arginine, betaine and creatine phosphate, N-acetylcysteine, coenzyme Q10 and dihydroquercetin; S-adenosylmethionine; coenzyme Q10 and dihydroquercetin, dihydroquercetin and lipoamide.

EFFECT: group of inventions enables relieving behavioural, neurological and psychic disorders by activating the osmoprotective and energetic systems, detoxification reaction systems of ammonium ions and other toxins, as well as the antioxidant systems of cerebral and hepatic cells.

5 cl, 3 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents the use of a compound which exhibits inhibitory activity on arginase as a therapeutically active agent for treating and/or preventing depression and/or depression-associated conditions.

EFFECT: invention provides extending the range of products for treating and/or preventing depression and/or depression-associated conditions.

9 cl, 3 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, namely to an oral pharmaceutical composition in the form of single doses, containing a combination of entacapone, levodopa and carbidopa, or salts thereof with one or more sugar alcohols; wherein entacapone is micronised together with one or more sugar alcohols, and a mixture of micronised entacapone and sugar alcohol prepared thereby has an average particle size less than 30 mcm.

EFFECT: invention enables higher dissolution rate in an aqueous media, absorption and bioavailability.

10 cl, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: claimed is application of levodopa and carbidopa for preparation of medication, intended for treatment of Parkinson's disease; or for treatment of sleep malfunction in patients with Parkinson's disease, for treatment of motive activity malfunction in patients with Parkinson's disease (versions), where medication contains levodopa and carbidopa in pharmaceutically effective quantity for continuous introduction into intestine for time period, which constitutes 24 h per day or more than one day. Sleep rating scale of patients with Parkinson's disease increased by 130% on the second night after starting twenty-four-hour introduction and remained within two following years.

EFFECT: twenty-four-hour introduction of medication replaces frequent per oral intake of medications, makes it possible to reach claimed prescriptions, with preservation of stable response to on medication introduction, which is not accompanied by development of clinically significant tolerance or side effects.

17 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to pharmaceutical industry and deals with solid pharmaceutical composition, possessing high physical strength. Claimed invention also presents method of manufacturing solid pharmaceutical composition. Claimed pharmaceutical composition contains 7 varicoloured types of granules in form of capsule. Granules contain, wt %: nikotinamide 1-35; pyridoxine 0.1-8; calcium pantitenate 0.1-15, thiamin 0.1-30; tryptophan 1-30; tocoferol 0.5-5; ascorbic acid 0.1-50; 5-hydroxyanthranyl acid 0.01-10; Riboflavin 0.1-10; folic acid 0.1-6; cyanocobalomin 0.001-6; isoleucin 0.5-10; leucin 0.5-15; lysine 0.5-20; phenylalanine 0.1-5; threonine 0.1-5.0; valin 0.1-8.0; methionine 0.1-15; lactose 1-4.0; ergocalcioferol 1-95.0 and auxiliary substances for obtaining granules.

EFFECT: claimed composition possesses excellent properties of medication release and digectionin application composition possesses hepatoprotective hypolipidemic immunostimulating and normalising kidney activity action.

2 cl. 2 ex. 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to composition for oral cavity care and methods of its application. Claimed is composition for oral cavity care, which contains: arginine, in free form or in form of salt in amount from 0.1 to 20 wt % of total composition weight; triclosan in amount from 0.01 to 5 wt % of total composition weight; anionic polymer, which is a copolymer of methyl vinyl ether and maleic anhydrate; anionic surfactant in amount from 0.01 to 10 wt % of total composition weight; soluble fluoride salt in amount from 0.01 to 2 wt % of total body weight, in order to provide 50-25000 ppm of weight of fluoride ions, in which soluble fluoride salt or source of fluoride ions is selected from sodium fluoride, sodium monofluorophosphate and their mixtures; and abrasive material, which contains fraction of minor particles, constituting at least about 5 wt % of total composition weight, and in said fraction minor particles have average diameter d50 smaller than 5 mcm.

EFFECT: application of composition for oral cavity care along with improved delivery of antibacterial agent provides additional advantages in acceleration of remineralisation and restoration of precarious affection foci due to combination of fluoride and arginine, as well as due to application of finely disperse abrasive as composition component.

11 cl, 1 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and to methods of their application. Claimed are compositions for oral cavity care, which contain effective amounts of arginine in free or salt form, anionic surface active substance, halogenated diphenyl ether, anionic polymer, and precipitated calcium carbonate, which has d50 from approximately 0.5 to approximately 3 micrometres.

EFFECT: compositions are efficient, in particular, for reduction of bacteria adherence to tooth surface in subject's oral cavity, in addition, chemical composition provides favourable effect in activation of remineralisation, elimination of pre-caries damage and strengthening healthy state of oral cavity along with intensification of taste properties of formulation of preparation for oral cavity care and increase of general acceptability pf product for consumers.

33 cl, 1 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacological industry, concerns creating a pharmaceutical composition (PC) developed on the basis of active substances recovered from plants. The pharmaceutical composition presented both in the liquid (aqueous-alcoholic), and dry form, may be used in clinical practice for preventing and treating oncological patients, age-related pathologies. The PC may be used in medicine, including pharmacology.

EFFECT: presented pharmaceutical composition on the basis on the active substances recovered from plant extracts, including ethanolic extract; it is easy-to-prepare, easy-to-use, easy-to-keep and has low price.

2 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, and concerns a combination of pyrrolidone-5-carboxylic acid, with at least one of the compounds specified in citrulline, arginine and asparagine in the racemic form or in the form of D- or L-isomer, and/or their salts to be used for treating atopic dermatitis. The present group of inventions also concerns a composition to be used for treating or preventing atopic dermatitis and containing pyrrolidone-5-carboxylic acid with one of the compounds specified in citrulline, arginine and asparagine in the racemic form or in the form of D- or L-isomer, and/or their salts in a physiologically acceptable carrier.

EFFECT: group of inventions provides better water absorption as compared with any of the declared amino acids.

17 cl, 3 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to acids which are suitable for use in medicine, having links of formulae (I) and (II) where n equals 1 or 2; A1 is selected from O or NR5, R5 is H or C1-4alkyl; A2 is O; R3 and R4 are selected from H, NH4 or an alkali metal; R1 and R2 are selected from C1-10alkyl, C6-20aryl, NH4, an alkali metal and an agent: taxane, camptothecin, doxorubicin, an acridine, coumarine, rhodamine, xanthene, cyanine or pyrene dye, a magnetic resonance imaging agent, a polydentate ligand or precursor thereof of formulae where R7 is selected from H, NH4 or an alkali metal, provided that one of R1 and R2 is said agent, conjugated with a polymer directly or through a linker group, and the ratio of the agent to the polymer conjugate ranges from 1 to 50% (wt/wt).

EFFECT: compared to a polyglutamic acid conjugate, the novel biodegradable conjugate has high solubility and provides the solution with high optical transparency in a wide pH range.

53 cl, 29 dwg, 38 ex, 3 tbl

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

Up!